Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

Inclusion Criteria: * patients diagnosed as malignant lymphoma * patients who were refractory to anthracycline or anthraquinone containing chemotherapy * patients who are going to receive ESHAP or CHASE treatment regimen * ECOG performance status =\< 2 * patients who have appropriate bone marrow, hepatic and renal functions * written informed consent Exclusion Criteria: * double cancer * history of bone marrow transplantation or PBSCT * more than 2 prior chemotherapy regimens * primary hematologic disease such as myelodysplastic syndrome * previous radiotherapy within 4 weeks of enrollment * woman of childbearing potential who were either pregnant, breast feeding * patients who participated in other clinical trials within the last 4 weeks of enrollment